Novo Nordisk successfully prices EUR 1.3 billion notes under its newly established Euro Medium Term Note programme

Bagsværd, Denmark, 27 May 2021 - Novo Nordisk today announced the successful launch and pricing of the first Eurobond issuance under its newly established EUR 5 billion Euro Medium Term Note (EMTN) programme in two tranches with an aggregate principal amount of EUR 1.3 billion.

The first tranche maturing on 4 June 2024 will be issued in an aggregate principal amount of EUR 650 million with a coupon of 0%. The second tranche maturing on 4 June 2028 will be issued in an aggregate principal amount of EUR 650 million with a coupon of 0.125%. Net proceeds of the issuances will be used by Novo Nordisk for general corporate purposes, including refinancing of the bridge loan facility established in connection with Novo Nordisk’s acquisition of Emisphere Technologies Inc. in 2020. Both bonds will be issued on 4 June 2021 and will be listed on Euronext Dublin.

Standard & Poor’s and Moody’s rated the notes at AA- and A1 in line with Novo Nordisk’s company ratings of AA- and A1 with stable outlook.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com , Facebook, Twitter , LinkedIn , YouTube .